Justin J. McAnear - 22 Mar 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role: Chief Financial Officer
Signature: /s/ Eric S. Whitaker, as Attorney-in-Fact for Justin J. McAnear
Issuer symbol: TXG
Transactions as of: 22 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Mar 2022, 17:14:39 UTC
Previous filing: 24 Feb 2022
Next filing: 17 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TXG	Class A Common Stock	Award	$0	+21,357	+55%	$0.000000	59,888	22 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXG	Stock Option (Right to Buy)	Award	$0	+53,392		$0.000000	53,392	22 Mar 2022	Class A Common Stock	53,392	$69.56	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2	This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.